{
  "resourceType" : "Composition",
  "id" : "COVID19IntensiveCareTreatmentGuideline",
  "meta" : {
    "profile" : ["https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/guideline"]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition COVID19IntensiveCareTreatmentGuideline</b></p><a name=\"COVID19IntensiveCareTreatmentGuideline\"> </a><a name=\"hcCOVID19IntensiveCareTreatmentGuideline\"> </a><a name=\"COVID19IntensiveCareTreatmentGuideline-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-guideline.html\">Clinical Practice Guideline</a></p></div><p><b>identifier</b>: Resource identifier/113-001</p><p><b>version</b>: 7.0</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/ceosys-code-system clinical-practice-guideline}, {https://data.cochrane.org/concepts/ e07eN1w1Rwswg4}\">Guidelines</span></p><p><b>category</b>: <span title=\"Codes:{https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/cs-guideline-stage-classification S3}\">Evidence- and consensus-based guideline</span></p><p><b>date</b>: 2022-03-01</p><p><b>author</b>: <a href=\"Organization-AWMFOrganization.html\">Organization Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V.</a></p><p><b>title</b>: Empfehlungen zur stationären Therapie von Patienten mit COVID-19 - Living Guideline</p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style=\"display: none\">*</td><td>Citation</td><td><a href=\"Citation-COVID19IntensiveCareTreatmentGuidelineCitation.html\">Citation COVID19_Intensive_Care_Treatment_Guideline</a></td></tr></table></div>"
  },
  "identifier" : [{
    "type" : {
      "coding" : [{
        "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
        "code" : "RI",
        "display" : "Resource identifier"
      }]
    },
    "system" : "https://www.awmf.org/",
    "value" : "113-001"
  }],
  "version" : "7.0",
  "status" : "final",
  "type" : {
    "coding" : [{
      "system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/ceosys-code-system",
      "code" : "clinical-practice-guideline"
    },
    {
      "system" : "https://data.cochrane.org/concepts/",
      "code" : "e07eN1w1Rwswg4",
      "display" : "Guidelines"
    }]
  },
  "category" : [{
    "coding" : [{
      "system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/cs-guideline-stage-classification",
      "code" : "S3",
      "display" : "Evidence- and consensus-based guideline"
    }]
  }],
  "date" : "2022-03-01",
  "author" : [{
    "reference" : "Organization/AWMFOrganization"
  }],
  "title" : "Empfehlungen zur stationären Therapie von Patienten mit COVID-19 - Living Guideline",
  "relatesTo" : [{
    "type" : "citation",
    "resourceReference" : {
      "reference" : "Citation/COVID19IntensiveCareTreatmentGuidelineCitation"
    }
  }],
  "section" : [{
    "title" : "Stationäre Therapie von COVID-19 Patienten",
    "code" : {
      "coding" : [{
        "system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/ceosys-code-system",
        "code" : "guideline-recommendation",
        "display" : "Clinical practice guideline recommendation"
      }]
    },
    "focus" : {
      "reference" : "PlanDefinition/COVID19VentilatedPatientsDexamethasoneApplicationPlan"
    },
    "text" : {
      "status" : "generated",
      "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><strong>Systemische Steroide:</strong> Bei Patienten mit COVID-19- und Sauerstoff-Bedarf (Niedrigfluss-Sauerstoff-Insufflation, High-Flow Nasal Cannula, Nichtinvasive Beatmung/CPAP, invasive Beatmung) soll eine Therapie mit systemischen Kortikosteroiden erfolgen. Die Therapie sollte mit 6 mg Dexamethason p.o. oder i.v. über zehn Tage erfolgen.</div>"
    }
  },
  {
    "title" : "Stationäre Therapie von COVID-19 Patienten",
    "code" : {
      "coding" : [{
        "system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/ceosys-code-system",
        "code" : "guideline-recommendation",
        "display" : "Clinical practice guideline recommendation"
      }]
    },
    "focus" : {
      "reference" : "PlanDefinition/COVID19NonVentilatedPatientsDexamethasoneApplicationPlan"
    },
    "text" : {
      "status" : "generated",
      "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><strong>Systemische Steroide:</strong> Bei Patienten mit moderater Erkrankung (hospitalisiert ohne Notwendigkeit von Niedrigfluss-Sauerstoff-Insufflation) soll keine Therapie mit systemischen Kortikosteroiden erfolgen.</div>"
    }
  }]
}